Induction of Immune Responses in Mice and Monkeys to Ebola Virus after Immunization with Liposome-Encapsulated Irradiated Ebola Virus: Protection in Mice Requires CD4 + T Cells
Open Access
- 15 September 2002
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (18) , 9176-9185
- https://doi.org/10.1128/jvi.76.18.9176-9185.2002
Abstract
Ebola Zaire virus (EBO-Z) causes severe hemorrhagic fever in humans, with a high mortality rate. It is thought that a vaccine against EBO-Z may have to induce both humoral and cell-mediated immune responses to successfully confer protection. Because it is known that liposome-encapsulated antigens induce both antibody and cellular responses, we evaluated the protective efficacy of liposome-encapsulated irradiated EBO-Z [L(EV)], which contains all of the native EBO-Z proteins. In a series of experiments, mice immunized intravenously with L(EV) were completely protected (94/94 mice) against illness and death when they were challenged with a uniformly lethal mouse-adapted variant of EBO-Z. In contrast, only 55% of mice immunized intravenously with nonencapsulated irradiated virus (EV) survived challenge, and all became ill. Treatment with anti-CD4 antibodies before or during immunization with L(EV) eliminated protection, while treatment with anti-CD8 antibodies had no effect, thus indicating a requirement for CD4+ T lymphocytes for successful immunization. On the other hand, treatment with either anti-CD4 or anti-CD8 antibodies after immunization did not abolish the protection. After immunization with L(EV), antigen-specific gamma interferon (IFNγ)-secreting CD4+ T lymphocytes were induced as analyzed by enzyme-linked immunospot assay. Anti-CD4 monoclonal antibody treatment abolished IFNγ production (80 to 90% inhibition compared to that for untreated mice). Mice immunized with L(EV), but not EV, developed cytotoxic T lymphocytes specific to two peptides (amino acids [aa] 161 to 169 and aa 231 to 239) present in the amino-terminal end of the EBO-Z surface glycoprotein. Because of the highly successful results in the mouse model, L(EV) was also tested in three cynomolgus monkeys. Although immunization of the monkeys with L(EV)-induced virus-neutralizing antibodies against EBO-Z caused a slight delay in the onset of illness, it did not prevent death.Keywords
This publication has 31 references indexed in Scilit:
- Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral ReplicationJournal of Virology, 2001
- Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral NucleoproteinJournal of Virology, 2001
- Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cellsAdvanced Drug Delivery Reviews, 2000
- Evaluation of Immune Globulin and Recombinant Interferon‐α2b for Treatment of Experimental Ebola Virus InfectionsThe Journal of Infectious Diseases, 1999
- DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal ChallengeVirology, 1998
- A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.The Journal of Experimental Medicine, 1996
- Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigenVaccine, 1995
- Liposomes as Carriers of Peptide Antigens: Induction of Antibodies and Cytotoxic T Lymphocytes to Conjugated and Unconjugated PeptidesImmunological Reviews, 1995
- Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virusVirus Research, 1993
- H-2Kd-restricted antigenic peptides share a simple binding motif.The Journal of Experimental Medicine, 1991